Is this you? Create Your Porfile
Avatar

Bilodeau Mark T

Merck & Co.

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where Bilodeau Mark T is active.

Explore More

Publication

Featured researches published by Bilodeau Mark T.

Archive | 2008

DECAHYDROQUINOLINE ANALOGS AS CB2 RECEPTOR MODULATORS

Bilodeau Mark T; Kett Nathan R; Lindsley Craig; Manley Peter J; Melamed Jeffrey Y; Paone Daniel Vincent; Trotter B Wesley; Wu Zhicai

Archive | 2016

METANOISOINDOLES Y DIONAS DE ÉSTOS COMO AGENTES ANTI-PSICÓTICOS.

Bilodeau Mark T; Nanda Kausik K; Trotter Wesley B

Archive | 2014

COMPOSTO, USO DE UM COMPOSTO, E, MÉTODOS PARA TRATAR UMA CONDIÇÃO E UMA DOENÇA, E PARA INTENSIFICAR A COGNIÇÃO EM UM PACIENTE MAMÍFERO

Bilodeau Mark T; Nanda Kausik K; Trotter B Wesley

Archive | 2008

composto ou sal farmaceuticamente aceitável do mesmo, método de tratamento de uma condição em um mamìfero, formulação farmacêutica, e, composição farmacêutica

Bilodeau Mark T; Wu Zhicai; Hartnett John

Archive | 2008

Tyrosinkinaseinhibitorer, farmasoytisk preparat inneholdende disse forbindelser, og anvendelse derav.

Bilodeau Mark T; Hungate Randall W; Arrington Kenneth L; Fraley Mark E; Hoffman William F; Kim Yuntae; Hartman George D

Archive | 2008

Türosiinkinaasi pärssiv ühend, seda sisaldav farmatseutiline kompositsioon ning ühendi kasutamine

Arrington Kenneth L; Bilodeau Mark T; Fraley Mark E; Hartman George D; Hoffman William F; Hungate Randall W; Kim Yuntae

Archive | 2007

1, 1, 2, 2-TETRA (HETERO) ARYLETHANES OU 1, 1, 2-TRI (HETERO) ARYLE-2-HETEROCYCLYLETHANES COMME INHIBITEURS DES CANAUX POTASSIQUES

Bilodeau Mark T; Wu Zhicai; Hartnett John

Archive | 2007

1,1,2,2-tetra(hetero)aryletaner eller 1,1,2-tri(hetero)aryl-2-heterosyklyletaner som kaliumkanalinhibitorer

Bilodeau Mark T; Wu Zhicai; Hartnett John

Archive | 2006

DERIVADOS DE 1,1,2,2-TETRA(HETERO)ARILETANO O 1,1,2-TRI(HETERO)CICLILETANO COMO INHIBIDORES DEL CANAL DE POTASIO

Bilodeau Mark T; Wu Zhicai; Hartnett John

Archive | 2005

Tyrosine Kinase Inhibitors, Pharmaceutical Compositions Containing Them and Use Thereof

Arrington Kenneth L; Bilodeau Mark T; Fraley Mark E; Hartman George D; Hoffman William F; Hungate Randall W; Kim Yuntae

Explore More

Collaboration

Dive into the Bilodeau Mark T's collaboration.

Top Co-Authors
Avatar

Hartman George D

Merck

View shared research outputs
Top Co-Authors
Avatar

Fraley Mark E

Merck

View shared research outputs
Top Co-Authors
Avatar

Hoffman William F

Merck

View shared research outputs
Top Co-Authors
Avatar

Wu Zhicai

Merck

View shared research outputs
Top Co-Authors
Avatar

Hungate Randall W

Merck

View shared research outputs
Top Co-Authors
Avatar

Manley Peter J

Merck

View shared research outputs
Top Co-Authors
Avatar

Trotter B Wesley

Merck

View shared research outputs
Top Co-Authors
Avatar

Kett Nathan R

Merck

View shared research outputs
Top Co-Authors
Avatar

Lindsley Craig

Merck

View shared research outputs
Top Co-Authors
Avatar

Melamed Jeffrey Y

Merck

View shared research outputs
Explore More
Researchain Logo
Decentralizing Knowledge